Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.60 |
| ▸ | BRAF | P15056 | 7/20 | 0.60 |
| ▸ | RAF1 | P04049 | 6/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.54 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.54 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167291 | 0.89 | KDR (0.74) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL4933174 | 0.88 | KDR (0.70) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL3177365 | 0.87 | KDR (0.61) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL4933039 | 0.87 | KDR (0.71) | KDRBRAFRAF1MAPK14TNNI3K | |
| Dimethylamine SCHEMBL4937315 | 0.85 | RAF1 (0.61) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL4937306 | 0.83 | KDR (0.59) | KDRBRAFRAF1MAPK14TNNI3K | |
| Diethylamine SCHEMBL4940356 | 0.82 | KDR (0.56) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL3166295 | 0.82 | KDR (0.79) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL4940351 | 0.81 | KDR (0.59) | KDRBRAFRAF1MAPK14TNNI3K | |
| SCHEMBL3174505 | 0.80 | CDK8 (0.71) | KDRBRAFRAF1MAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | KDR 1309/4885BRAF 65/4885RAF1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.